Related Experiment Video
Updated: Jan 13, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
[Menopause, hormone therapy and cardiovascular risk]
Geneviève Plu-Bureau1, Iphigénie Cavadias1, Brigitte Raccah-Tebeka2
1Unité de gynécologie endocrinienne, hôpital Port-Royal, Université Paris Cité, Paris, Inserm UMR 1153, Obstetrical, Perinatal, Paediatric Life course Epidemiology (OPPaLE), centre d'épidémiologie et de statistiques Sorbonne Paris Cité (CRESS), Paris, France.
Abstract:
Cardiovascular disease is currently the second leading cause of death among women in France. The menopause period is probably the ideal time to screen for all cardiovascular risk factors. This step is essential before offering menopausal hormone therapy to women suffering from disabling climacteric syndrome. If such treatment is authorized, transdermal estradiol combined with natural progesterone is the safest treatment for women with no history of hysterectomy. The tolerability of this treatment, as well as all cardiovascular risk factors, must be assessed annually in order to optimize the benefit/risk balance.
Related Concept Videos
Menopause
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
Hormonal Regulation of Blood Pressure
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Mitral Valve Prolapse III: Nursing Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

